Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cellectar Biosciences, Inc. - Common Stock (NQ: CLRB )

0.2908 +0.0098 (+3.49%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 806,375
Open 0.2750
Bid (Size) 0.2800 (21)
Ask (Size) 0.2948 (3)
Prev. Close 0.2810
Today's Range 0.2750 - 0.2977
52wk Range 0.2240 - 4.450
Shares Outstanding 40,566,534
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Cellectar Biosciences to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
From Cellectar Biosciences, Inc.
Via GlobeNewswire
Cellectar Biosciences to Highlight 2025 Strategic Initiatives at Upcoming Biotech Showcase during the JP Morgan Healthcare Conference
From Cellectar Biosciences, Inc.
Via GlobeNewswire

Performance

YTD
-10.50%
-10.50%
1 Month
+20.07%
+20.07%
3 Month
-83.57%
-83.57%
6 Month
-85.81%
-85.81%
1 Year
-91.56%
-91.56%

More News

Read More
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Crude Oil Jumps 2%; Macy's Lowers Earnings Forecast
Via Benzinga
Exposures Fossil Fuels
Earnings Preview For Cellectar Biosciences
Via Benzinga
Cellectar Biosciences Stock Plunges As Cancer-Focused Cancer Firm Pursues Strategic Options
Via Benzinga
Exposures Product Safety
Nasdaq Surges Over 1%; US Inflation Rises In-Line With Expectations
Via Benzinga
Topics Economy
Exposures Interest Rates
Why Stitch Fix Shares Are Trading Higher By Around 21%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Cellectar Biosciences Provides Strategic Update on Clinical Development, Pipeline Programs and Corporate Restructuring
From Cellectar Biosciences, Inc.
Via GlobeNewswire
Cellectar Biosciences Reports Financial Results for Q3 2024 and Provides a Corporate Update
From Cellectar Biosciences, Inc.
Via GlobeNewswire
Earnings Scheduled For November 18, 2024
Via Benzinga
Cellectar Biosciences and NorthStar Medical Radioisotopes Announce Partnership for Supply of Actinium-225
From Cellectar Biosciences, Inc.
Via GlobeNewswire
Cellectar Biosciences and SpectronRx Partner to Manufacture Novel Phospholipid Radioconjugate for the Treatment of Cancer
From Cellectar Biosciences, Inc.
Via GlobeNewswire
Gold Moves Higher; Coca-Cola Increases FY24 Forecast
Via Benzinga
Why Comcast Shares Are Trading Lower By 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Crude Oil Down 2%; GE Aerospace Earnings Top Views
Via Benzinga
Exposures Fossil Fuels
Cancer-Focused Cellectar Biosciences Stock Trades Lower Despite Meeting Goal In Blood Cancer Study
Via Benzinga
CLRB Stock Earnings: Cellectar Biosciences Misses EPS for Q1 2024
Via InvestorPlace
Hedgeye Warns That Reddit (RDDT) Stock Will Fall 50%
Via InvestorPlace
Why Is Gamida Cell (GMDA) Stock Down 82% Today?
Via InvestorPlace
CLRB Stock Earnings: Cellectar Biosciences Beats EPS for Q4 2023
Via InvestorPlace
Earnings Scheduled For March 27, 2024
Via Benzinga
Cellectar Biosciences Is An 'Attractive Acquisition Target' According To This Analyst - Here's Why
Via Benzinga
Why Is Cancer-Focused Cellectar Biosciences Stock Trading Higher Today?
Via Benzinga
Wells Fargo Is Warming Up to Enphase Energy (ENPH) Stock
Via InvestorPlace
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.